Advanced Molecular Diagnostic Systems

1 Dalmore Drive, Scoresby, Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817 www.generabiosystems.com

Tuesday 14 May 2013

ASX Announcement - GENERA BIOSYSTEMS LIMITED (ASX:GBI) -

EXECUTIVE DIRECTOR APPOINTMENT

Genera Biosystems Limited ('Genera') is pleased to announce the appointment of Richard
Hannebery to the role of Executive Director - Corporate Development.
Commenting on the appointment, Executive Chairman Lou Panaccio said "Richard has had a long association with Genera Biosystems. He was a director of the company from 2005 to 2008, prior to the company's listing on ASX. At Genera, he previously held the role of Corporate Development Director and was responsible for the initial agreements struck with both Healthscope and Sonic Healthcare. Richard has also been intimately involved with the financing of the company's operations to date, a role he will continue to fill when required.
"Richard's knowledge of Genera's technology is first-rate, as is his understanding of the dynamics of relevant product markets. Richard also has a thorough understanding of the process involved in successfully negotiating commercial deals outside of R&D and I am delighted that he has accepted our offer to rejoin the board and take on this key role."
Richard Hannebery commented, "I believe that Genera has tremendous latent value in its Ampasand technology platform. The underlying intellectual property is extremely robust with a sound freedom to operate position and with marginal royalty stack involved in bringing relevant products to market, a key consideration in the eyes of any potential partner.
"The two lead products developed to date possess attractive economics and we are confident that we can replicate this with additional tests that will be added to the menu. The PapType simultaneous genotyping HPV assay is well positioned as government healthcare agencies around the world move closer to adoption of HPV testing as the primary screening tool in the fight against cervical cancer in women.
"Our challenge now is to deliver attractive commercial distribution deals, both direct and via well- credentialed 3rd parties, to ensure that shareholders receive an outstanding return on the capital they have entrusted with Genera in bringing the Ampasand technology to market.
"Genera is fortunate to have assembled a highly complementary expert team and I look forward to working productively with them to deliver the outcome that our team and our shareholders deserve."

Advanced Molecular Diagnostic Systems



For further information please contact:
Mr Lou Panaccio
Executive Chairman
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
Lou.Panaccio@generabiosystems.com

About Genera Biosystems:

Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product, PapType®, a test which simultaneously detects and genotypes human papillomavirus, is registered in Australia and
the European Union.

distributed by